Differential effects of C-reactive protein levels on voriconazole metabolism at three age groups in allogeneic hematopoietic cell transplant recipients

References

• Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman ANR, et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.Drug Metab Dispos. 2003;31(6):731–41.
   PubMed Web of Science ®Google Scholar
• Gautier-Veyret E, Bailly S, Fonrose X, Tonini J, Chevalier S, Thiebaut-Bertrand A, et al. Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations. Pharmacogenomics. 2017;18(12):1119–23.
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole.Br J Clin Pharmacol. 2003;56 (Suppl 1):17–23.
   PubMed Web of Science ®Google Scholar
• Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 2003;31(5):540–7.
   PubMed Web of Science ®Google Scholar
• Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB. Voriconazole. Clin Ther. 2003;25(5):1321–81.
   PubMed Web of Science ®Google Scholar
• Yanni SB, Annaert PP, Augustijns P, Bridges A, Gao Y, Benjamin DK, et al. Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes.Drug Metab Dispos. 2008;36(6):1119–25.
   PubMed Web of Science ®Google Scholar
• Lortholary O, Gangneux J-P, Sitbon K, Lebeau B, de Monbrison F, Le Strat Y, Coignard B, Dromer F, Bretagne S. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005-2007). Clin Microbiol Infect. 2011;17(12):1882–9.
   PubMed Web of Science ®Google Scholar
• Allegra S, De Francia S, De Nicolo A, Cusato J, Avataneo V, Manca A, et al. Effect of gender and age on voriconazole trough concentrations in Italian adult patients. Eur J Drug Metab Pharmacokinet. 2020;45(3):405–412.
   PubMed Web of Science ®Google Scholar
• Chen C, Yang T, Li X, Ma L, Liu Y, Zhou Y, et al. Population pharmacokinetics of voriconazole in chinese patients with hematopoietic stem cell transplantation. Eur J Drug Metab Pharmacokinet. 2019;44(5):659–68.
   PubMed Web of Science ®Google Scholar
• Wei X, Zhao M, Fu P, Xiao X. Risk factors associated with insufficient and potentially toxic voriconazole plasma concentrations: an observational study. J Chemother. (Florence, Italy). 2019;31(7–8):401–7.
   PubMed Web of Science ®Google Scholar
• Blanco-Dorado S, Cea-Arestin C, González Carballo A, Latorre-Pellicer A, Maroñas Amigo O, Barbeito Castiñeiras G, et al. An observational study of the efficacy and safety of voriconazole in a real-life clinical setting. J Chemother. 2019;31(1):49–57.
   PubMed Web of Science ®Google Scholar
• Seifert SM, Castillo-Mancilla JR, Erlandson KM, Anderson PL. Inflammation and pharmacokinetics: potential implications for HIV-infection. Expert Opin Drug Metab Toxicol. 2017;13(6):641–50.
   PubMed Web of Science ®Google Scholar
• Shah RR, Smith RL. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine. Drug Metab Dispos. 2015;43(3):400–10.
   PubMed Web of Science ®Google Scholar
• van Wanrooy MJP, Span LFR, Rodgers MGG, van den Heuvel ER, Uges DRA, van der Werf TS, et al. Inflammation is associated with voriconazole trough concentrations. Antimicrob Agents Chemother. 2014;58(12):7098–101.
   PubMed Web of Science ®Google Scholar
• Naito T, Yamada T, Mino Y, Kawakami J. Impact of inflammation and concomitant glucocorticoid administration on plasma concentration of triazole antifungals in immunocompromised patients. Clin Chim Acta. 2015;441:127–32.
   PubMed Web of Science ®Google Scholar
• Veringa A, ter Avest M, Span LFR, van den Heuvel ER, Touw DJ, Zijlstra JG, et al. Voriconazole metabolism is influenced by severe inflammation: a prospective study. J Antimicrob Chemother. 2017;72(1):261–7.
   PubMed Web of Science ®Google Scholar
• Encalada Ventura MA, Span LF, van den Heuvel ER, Groothuis GM, Alffenaar JW. Influence of inflammation on voriconazole metabolism. Antimicrob Agents Chemother. 2015;59(5):2942–3.
   PubMed Web of Science ®Google Scholar
• Encalada Ventura MA, van Wanrooy MJP, Span LFR, Rodgers MGG, van den Heuvel ER, Uges DRA, et al. Longitudinal analysis of the effect of inflammation on voriconazole trough concentrations. Antimicrob Agents Chemother. 2016;60(5):2727–31.
   PubMed Web of Science ®Google Scholar
• Yasu T, Konuma T, Kato S, Kurokawa Y, Takahashi S, Tojo A. Serum C-reactive protein levels affect the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients. Leuk Lymphoma. 2017;58(11):2731–3.
   PubMed Web of Science ®Google Scholar
• Gautier‐Veyret E, Truffot A, Bailly S, Fonrose X, Thiebaut‐Bertrand A, Tonini J, et al. Inflammation is a potential risk factor of voriconazole overdose in hematological patients. Fundam Clin Pharmacol. 2018;33(2):232–238.
   PubMed Web of Science ®Google Scholar
• Ter Avest M, Veringa A, van den Heuvel ER, Kosterink JGW, Schölvinck EH, Tissing WJE, et al. The effect of inflammation on voriconazole trough concentrations in children. Br J Clin Pharmacol. 2017;83(3):678–80.
   PubMed Web of Science ®Google Scholar
• Spriet I, Cosaert K, Renard M, Uyttebroeck A, Meyts I, Proesmans M, et al. Voriconazole plasma levels in children are highly variable. Eur J Clin Microbiol Infect Dis. 2011;30(2):283–7.
   PubMed Web of Science ®Google Scholar
• Yanni SB, Annaert PP, Augustijns P, Ibrahim JG, Benjamin DK Jr., Thakker DR. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos. 2010;38(1):25–31.
   PubMed Web of Science ®Google Scholar
• Man M, Farmen M, Dumaual C, Teng CH, Moser B, Irie S, et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol. 2010;50(8):929–40.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. VFEND (Voriconazole) [cited 2019 Dec]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021630s034,021266s045,021267s055lbl.pdf
   Google Scholar
• Yamada T, Mino Y, Yagi T, Naito T, Kawakami J. Rapid simultaneous determination of voriconazole and its N-oxide in human plasma using an isocratic high-performance liquid chromatography method and its clinical application. Clin Biochem. 2012;45(1–2):134–8.
   PubMed Web of Science ®Google Scholar
• Luo X, Huang L, Li T, Lei H, Xue L, Xue X, et al. High performance liquid chromatography coupling with photo-diode array detector method for monitoring voriconazole and its main metabolite N-oxidized voriconazole and its application to medication guidance for childhood leukemia. Chin Pharm J. 2019;54(14):1169–75.
   Google Scholar
• Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos. 2008;36(2):205–16.
   PubMed Web of Science ®Google Scholar
• Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. AAC. 2009;53(3):935–44.
   Google Scholar
• Zane NR, Chen Y, Wang MZ, Thakker DR. Cytochrome P450 and flavin-containing monooxygenase families: age-dependent differences in expression and functional activity. Pediatr Res. 2018;83(2):527–35.
   PubMed Web of Science ®Google Scholar
• Upreti V V, Wahlstrom J L. Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. The Journal of Clinical Pharmacology. 2016;56(3):266–83.
   PubMed Web of Science ®Google Scholar
• Mahmoudi M, Brenner T, Hatiboglu G, Burhenne J, Weiss J, Weigand M A, Haefeli W E. Substantial Impairment of Voriconazole Clearance by High-Dose Meropenem in a Patient With Renal Failure. Clinical Infectious Diseases. 2017;65(6):1033–6.
   PubMed Web of Science ®Google Scholar
• Truffot A, Thiebaut-Bertrand A, Chapuis C, Stanke-Labesque F, Gautier-Veyret E. Inhibition of Voriconazole Metabolism by Meropenem: A Role for Inflammation?. Clinical Infectious Diseases. 2018;66(10):1643–4.
   PubMed Web of Science ®Google Scholar
• Shi C, Xiao Y, Mao Y, Wu J, Lin N. Voriconazole: A Review of Population Pharmacokinetic Analyses. Clin Pharmacokinet. 2019;58(6):687–703.
   PubMed Web of Science ®Google Scholar
• Mafuru M, Wu S, He S, Lu X, Huang J, Jiang H. The Influence of Proinflammatory Cytokines on Voriconazole Trough Concentration in Patients With Different Forms of Hematologic Disorders. The Journal of Clinical Pharmacology. 2019;59(10):1340–50.
   PubMed Web of Science ®Google Scholar
• Vreugdenhil B, Van Der Velden W J F M, Feuth T, Kox M, Pickkers P, Van De Veerdonk F L, Blijlevens N M A, Brüggemann R J M. Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole. Br J Clin Pharmacol. 2018;84(9):1980–8.
   PubMed Web of Science ®Google Scholar